Physician profile

Zia Rab

Interventional Cardiology · Lakeland, FL

NPI 1548548332

$7,422.98

in general payments reported to CMS, 2019-2025

36 companies · $1,113 in 2025

The $1,113 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,340.11
Travel and Lodging$274.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $2,289.12 2019-2024 Esprit
Edwards Lifesciences Corporation $1,015.69 2019-2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia
Boston Scientific Corporation $814.49 2019-2025 Watchman Flx, Avvigo Guidance System, Varithena Administration Pack
Medtronic, INC. $450.27 2021-2024 Corevalve Evolut R, Resolute Onyx, Hawkone
E.R. Squibb & Sons, L.L.C. $402.67 2019-2025 Eliquis, Camzyos
Novartis Pharmaceuticals Corporation $278.06 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $250.46 2019-2025 Jardiance
Abiomed $241.15 2020-2025
Baylis Medical Company INC $149.18 2019
Philips North America LLC $146.41 2020-2025 IV Other, (Br5) Peripheral Ivus
Cardiovascular Systems INC. $132.71 2019-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $129.58 2022-2025 Lifevest
Merck Sharp & Dohme LLC $126.19 2022-2024 Verquvo
Janssen Pharmaceuticals, INC $110.84 2020-2024 Xarelto
Pfizer INC. $110.63 2019-2023
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $71.65 2019-2025 Repatha
Astrazeneca Pharmaceuticals LP $67.47 2019-2023 Farxiga
Alnylam Pharmaceuticals INC. $64.67 2022-2024 Onpattro
Bayer Healthcare Pharmaceuticals INC. $59.60 2021-2022
Surmodics, INC. $59.35 2024-2025 Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Pounce Thrombectomy
Shockwave Medical, INC $58.74 2025
Medtronic Vascular, INC. $55.31 2019-2020
Inari Medical, INC. $53.17 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Bard Peripheral Vascular, INC. $37.77 2024-2025 Rotarexs 6 F X 135 Cm
Tactile Systems Technology INC $36.39 2025 Flexitouch Plus, Nimbl
Inspiremd LTD $31.30 2025 Cguard Prime Carotid Stent System
Route 92 Medical, INC. $26.68 2025
Terumo Medical Corporation $24.26 2025 Azur Cx Detachable
Sirtex Medical INC $20.93 2025 Lava Les (Liquid Embolic System)
Nevro Corp. $17.82 2024 Senza
Esperion Therapeutics, INC. $16.82 2020
Actelion Pharmaceuticals US, INC. $15.68 2019
Penumbra, INC. $15.66 2022
Angiodynamics, INC. $15.55 2023 Bioflo
Regeneron Healthcare Solutions, INC. $14.11 2019
Baylis Medical Technologies INC. $12.60 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Zia Rab

$7,422.98

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,113 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/1383376/zia-rab

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.